Hans Jeppsson
Director of Finance/CFO at VICORE PHARMA HOLDING AB
Net worth: 6 865 $ as of 2024-03-30
Hans Jeppsson active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VICORE PHARMA HOLDING AB | Director of Finance/CFO | 2016-12-31 | - |
| Public Communications Contact | 2016-12-31 | - | |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Corporate Officer/Principal | - | - |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Director/Board Member | - | - |
Career history of Hans Jeppsson
Former positions of Hans Jeppsson
| Companies | Position | Start | End |
|---|---|---|---|
| Danske Bank A/S (Sweden) | Analyst-Equity | - | - |
Training of Hans Jeppsson
| University of Gothenburg | Doctorate Degree |
| Handelshögskolan i Göteborg | Doctorate Degree |
Statistics
International
| Sweden | 7 |
Operational
| Doctorate Degree | 2 |
| Graduate Degree | 2 |
| Analyst-Equity | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| VICORE PHARMA HOLDING AB | Health Technology |
| Private companies | 3 |
|---|---|
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Health Technology |
| Danske Bank A/S (Sweden) | Finance |
INIM Pharma AB
INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Hans Jeppsson
- Experience